Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1196 - Tuberculosis exposure and the risk of cancer


19 Dec 2015


Poster presentation 1


Vincent Yi-Fong Su


Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526


V.Y. Su

Author affiliations

  • Department Of Chest Medicine, Taipei Veterans General Hospital, 112 - Taipei/TW


Abstract 1196


The association of latent tuberculosis infection (LTBI) with subsequent cancer remains unclear. We investigated the risk of future cancer among tuberculosis (TB) contacts with or without subsequent TB activation.


Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study. TB Contacts during 1997–2012 were included as the study cohort. Patients with antecedent cancer and TB were excluded. Data from 11,522 TB contacts and 46,088 age-, sex-, and enrollment date–matched subjects during 1997–2012 were analyzed. The two cohorts were monitored until December 31, 2012 for incidence of cancer and TB infection. LTBI was defined as a TB contact with subsequent TB activation. The primary endpoint was occurrence of newly diagnosed cancer.


There was no difference in cancer development between the TB contact cohort and comparison cohort (log-rank test, p = 0.714). After multivariate adjustment, the hazard ratio (HR) for cancer among the LTBI patients was 2.29 [95% confidence interval (CI), 1.26–4.17; p = 0.007]. There was increase in cancer incidences for several specific cancer types, including multiple myeloma (HR 340.28), lung (HR 2.69), kidney and bladder (HR 6.16), hepatobiliary (HR 2.36), and gastrointestinal (HR 2.99) cancers. None of the 136 TB contacts who received isoniazid prophylaxis developed cancer.


TB exposure did not increase the risk of future cancer. LTBI patients had a higher risk of future cancer. However, isoniazid prophylaxis may reduce this risk.

Clinical trial identification

This study is not a clinical trial.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings